Project Grant R01CA312608
Award Date 8/26/26
Completion Date 7/31/31
Dollars Obligated $613K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pleasanton, CA 94588, USA
Similar Awards
- The National Cancer Institute awarded Kaiser Foundation Hospitals $733,410 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the real-world effects of incretin mimetics on cancer risk using targeted learning and causal inference methods. Kaiser Permanente's Kaiser Foundation Research Institute, based in Pleasanton, California, will conduct a target trial emulation study assessing sustained incretin mimetic use—particularly GLP-1 receptor...
- The National Cancer Institute awarded Kaiser Foundation Hospitals $440,440 on August 1, 2026, to develop a statistical framework for predicting surveillance mammography failure in breast cancer survivors under the Cancer Cause and Prevention Research program (CFDA 93.393). The project addresses the clinical challenge that surveillance mammography in breast cancer survivors detects only 70.4 percent of recurrences, missing nearly 30 percent of second breast cancers. Kaiser will build a risk...
- Federal Grant Award Summary Kaiser Foundation Hospitals (Kaiser Permanente), through its Kaiser Foundation Research Institute, received a $658,743 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded on August 25, 2025, with a completion date of July 31, 2030. The grant supports development and validation of prediction models for functional trajectories, cognitive outcomes, and quality of life among adults aged 65 and older...
- The National Cancer Institute awarded Cedars-Sinai Medical Center $574,557 on June 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to integrate life expectancy estimates into electronic health record decision support for men with prostate cancer. The project addresses life expectancy as a critical triage factor in prostate cancer treatment planning. Life expectancy assessment determines eligibility for aggressive treatment versus observation; men with limited...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $575,178 on May 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop radiopharmaceuticals termed "restricted interaction peptides" (RIPs) targeting human kallikrein 2 for molecularly targeted radiotherapy of metastatic castration-resistant prostate cancer. The project tests whether RIPs—low molecular weight peptides internally cleaved by tumor...
- The National Cancer Institute awarded the Regents of the University of Michigan $490,836 on June 19, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to fund research examining transitions from active surveillance to observation in prostate cancer management among older men. The research addresses a clinical gap in understanding how and when men aged 65 and older who are too old or too sick with comorbidities to benefit from cancer treatment transition from active...
- The U.S. National Cancer Institute (NCI) awarded a $158,290 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Kaiser Foundation Hospitals to conduct a study on "Estimating Overdiagnosis After Implementation of Lung Cancer Screening in Community-Based Healthcare Systems." This 2-year project, running from July 2024 to July 2026, aims to produce estimates of overdiagnosis among patients diagnosed with lung cancer who participated in lung cancer...
- The National Cancer Institute awarded $460,134 to Veterans Medical Research Foundation of San Diego on July 20, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct secondary analysis of Veterans Health Administration data examining prostate-specific antigen screening benefits and harms in Black men. The research addresses a critical evidence gap: Black men comprised only 4.4 percent of participants in landmark PSA screening trials despite facing 64 percent...
- The National Institutes of Health National Cancer Institute awarded Clark Atlanta University, Inc., $194,929 on July 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to examine the mechanisms of response to anti-androgen therapies in aggressive prostate cancer. The project investigates why patients with aggressive prostate cancer initially respond strongly to androgen deprivation therapy (ADT) but ultimately develop resistance and progress to castration-resistant prostate cancer...
- This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...